[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"minimal-residual-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:minimal-residual-disease":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,44,68,93,114,167,220,251,280,308,338,362,384,411,430,452,474,502,526,555,582,607,630,655,679],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100538206","french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-frenchmrdcrc-100538206",false,"NCT06287814","French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients","FRENCH.MRD.CRC PART I Inclusion criteria\n\n* Colon or rectal cancer, clinical tumor stage I-III.\n* Patient 18 years or older.\n* Scheduled for curative intent resection surgery (including \"compromised\" curative resections).\n\nExclusion criteria\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Verified distant metastases.\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.\n\nFRENCH.MRD.CRC PART II Inclusion criteria\n\n* Participation in FRENCH.MRD.CRC part 1 - SURGERY\n* Colorectal cancer, UICC stage III\n* Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer\n* Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)\n* Treated with neoadjuvant chemo-radiation therapy\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.",[25,26,27,28],"Colorectal Cancer","Stage III Colon Cancer","Minimal Residual Disease","Liquid Biopsy",[30,27,28],"Stage III colorectal cancer","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":35},"2024-04-11",{"date":39,"type":21},"2033-10-31",{"name":41,"class":42},"University Hospital, Montpellier","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100538199","french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-frenchmrdcrlm-100538199","NCT06287723","French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Colorectal With Liver Metastasis Patients","Inclusion Criteria:\n\n* Patient 18 years or older.\n* Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT.\n* Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor.\n* Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Extrahepatic metastases\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Liver cirrhosis\n* CRLM intervention\u002Fsurgery cannot be\u002Fwas not performed with curative intent\n* No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor)\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":52,"type":21},30,"Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.",[25,55,56,27,28,57],"Liver Metastases","Stage IV Colorectal Cancer","ctDNA",[59,27,60],"Stage IV colorectal cancer","Liquid biopsy",{"date":34,"type":35},{"date":63,"type":35},"2024-04-15",{"date":65,"type":21},"2029-04-15",{"name":41,"class":42},2,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100603404","phase-2-a-phase-2-trial-of-fruquintinib-and-tislelizumab-in-ctdna-defined-minimal-residual-disease-in-colorectal-cancer-after-completion-of-adjuvant-chemotherapy-100603404","NCT07136077","A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","Eligibility Criteria\n\n* Participants must have histologically or cytologically confirmed microsatellite stable (MSS) colorectal adenocarcinoma.\n* Participants must have completed curative intent treatments of stages II, III, or IV colorectal cancer that must include ≥ 3 months of oxaliplatin containing chemotherapy.\n* No evidence of radiographic disease within 28 days (before or after) a positive ctDNA assay.\n* Participants must have minimal residual disease as defined by positive ctDNA assay by Signatera MRD assay.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count of ≥1.0×109\u002FL\n  * Platelet count of ≥100×109\u002FL\n  * Hemoglobin ≥9 g\u002FdL\n  * Serum total bilirubin ≤1.5× upper limit of normal (ULN) (total bilirubin must be \\\u003C3× ULN for participants with documented Gilbert's syndrome).\n  * Participants must have ALT and AST ≤5× ULN.\n  * Urine protein ≤1+ by dipstick or 24-hour urine protein \\\u003C1 g\u002F24 hours. Participants with 2+ proteinuria by dipstick must undergo 24-hour urine collection to assess urine protein level.\n  * Creatinine creatinine clearance (CrCl) ≥30 mL\u002Fmin per Cockcroft-Gault.\n  * International normalized ratio (INR) and activated prothrombin time (aPTT) ≤1.5 ULN unless the participant is receiving anticoagulation therapy and INR and aPTT values are within the intended therapeutic range.\n* ECOG performance status (PS) of 0 or 1.\n* Age ≥ 18 years.\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months after the end of study treatment. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:\n\n  * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n  * History of hysterectomy or bilateral salpingo-oophorectomy.\n  * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n  * History of bilateral tubal ligation or another surgical sterilization procedure.\n* Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study treatment administration.\n* Is able to understand and is willing to sign a written informed consent document.\n\nExclusion Criteria\n\n* Has other concomitant active, invasive malignancies that may interfere with ctDNA analysis (known clonal hematopoesis of unknown potential allowed).\n* Has serum electrolytes, potassium, calcium, or magnesium levels outside of the normal laboratory reference range which are clinically significant in the investigator's judgment.\n* Has significant concomitant health conditions including but not limited to severe autoimmune or cardiovascular disorders that may interfere with participation in the study.\n* Active autoimmune diseases or history of autoimmune diseases that may worsen or relapse per treating providers' evaluation.\n* Has a persistent adverse event from previous treatment, except alopecia and neuropathy, greater than or equal to grade 2 of the Common Toxicity Criteria for Adverse Events (CTCAE) v. 5.0\n* Systemic anti-neoplastic therapies or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy, and immunotherapy.\n* Systemic small molecule-targeted therapies (eg, tyrosine kinase inhibitors) within 5 halflives or 4 weeks (whichever is shorter) prior to the first dose of study drug.\n* Mean QT interval corrected by the method of Fridericia (QTcF) ≥480 ms.\n* Has another disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may (a) prohibit use of the investigational product, (b) affect interpretation of study results, or (c) put the participant at undue risk of harm\n* Has known hypersensitivity to the trial drugs or their excipients or is at risk of allergic of anaphylactic reaction to drug product according to the Investigator's judgement.\n* Is pregnant or lactating.\n* Is unable to take medication orally or has any other condition that investigators believe may affect absorption of the investigational product.\n* Is receiving any other investigational agent.\n* Any condition that requires systemic treatment with either corticosteroid (\\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first dose of study drug(s), with the following exceptions:\n\n  * Adrenal replacement (dose of ≤10 mg daily of prednisone or equivalent).\n  * Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with minimal systemic absorption.\n  * Short course (≤7 days) of corticosteroid prescribed prophylactically (eg, for contrast dye allergy) or for the treatment of a non-autoimmune condition (eg, delayed-type hypersensitivity reaction caused by contact allergen)\n* Live vaccine ≤28 days before the first dose of study drug(s). Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.\n* Known untreated or inadequately treated active hepatitis C, or chronic hepatitis B.\n* Known untreated or inadequately treated human immunodeficiency virus (HIV) infection.\n* Major surgery within 30 days before the first drug administration. Participants must have recovered adequately from the toxicity and\u002For complications from the intervention prior to the first dose of study drug(s).\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Any of the following cardiovascular risk factors:\n\n  * Acute myocardial infarction ≤6 months before the first dose of study drug(s).\n  * Heart failure meeting New York Heart Association Function Classification III or IV ≤6 months before the first dose of study drug(s)\n  * Ventricular arrhythmia Grade ≥2 in severity ≤6 months before the first dose of study drug(s).\n  * Cerebrovascular accident ≤12 months before the first dose of study drug(s).\n  * Uncontrolled hypertension that cannot be managed by standard antihypertension medications, which is specified as systolic pressure ≥140 mmHg and\u002For diastolic pressure ≥90 mmHg. The participant must have blood pressures below both limits. Repeated assessments are permitted.\n  * Syncope or seizure ≤28 days before the first dose of study drug(s).\n* Received strong inducers of cytochrome P450, family 3, subfamily A (CYP3A) taken within 2 weeks (or 5 times the t1\u002F2 of the drug, whichever is longer) prior to the first study treatment.\n* Active gastrointestinal and duodenal ulcers, ulcerative colitis, and other gastrointestinal disease: other conditions that the investigator determines to possibly cause gastrointestinal bleeding, perforation, and other conditions; or prior gastrointestinal perforation or gastrointestinal fistula that has not recovered after surgical treatment.\n* History or presence of clinically significant hemorrhage from any site (such as clinically significant melena, hematemesis, hemoptysis, fresh in stool) within 2 months before the screening.\n* History of arterial thrombus within the last 12 months.",{"count":75,"type":21},20,"INTERVENTIONAL",[78],"PHASE2","To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have \"positive\" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).",[27,81,25,82,83,57],"Adjuvant Chemotherapy","Fruquintinib","Tislelizumab","2026-05-28",{"date":86,"type":35},"2026-06-01",{"date":88,"type":35},"2025-09-18",{"date":90,"type":21},"2028-04-01",{"name":92,"class":42},"M.D. Anderson Cancer Center",{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":76,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":43},"100543635","phase-1-dose-escalation-and-expansion-study-of-trop2-car-engineered-il-15--transduced-cord-blood-derived-nk-cells-in-combination-with-cetuximab-in-patient-with-colorectal-cancer-crc-with-minimal-residual-disease-mrd-100543635","NCT06358430","Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)","Inclusion Criteria:\n\n1. Participants must be 18 years or older.\n2. Participants must be willing and able to provide informed consent.\n3. Willing and able to comply with clinical trial instructions and requirements. Individuals lacking the ability, based on reasonable medical judgment, to understand and appreciate the nature and consequences of participation in this study will not be eligible for participation.\n4. In both the dose escalation and dose expansion cohorts, participants must have documented colorectal cancer (CRC) with MRD following complete disease resection followed by standard-of-care adjuvant treatment. MRD is defined as NO evidence of radiological disease (including patients with undefinable lesion with max diameter \\\u003C1 cm or with a short axis \\\u003C 1cm for lymph nodes) and presence of circulating ctDNA in the bloodstream.\n5. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 3).\n6. Life expectancy \\> 3 months.\n7. A female patient is eligible to participate if at least one of the following conditions applies:\n\n   * Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 OR\n   * A WOCBP who agrees to follow the contraceptive guidelines in Appendix 4 during the study treatment period and for 6 months post TROP2-CAR-NK cell infusion.\n8. Female participants who become pregnant or suspect pregnancy must immediately notify their doctor. Females' participants who become pregnant will be taken off study.\n9. Male participants must agree to follow the contraceptive guidelines in Appendix 4 during the study treatment period and for 6 months post TROP2-CAR-NK cell infusion. Male participants who father a child or suspect that they have fathered a child must immediately notify their doctor.\n10. WOCBP must have a negative urine pregnancy test within 72 hours prior to the start of lymphodepleting chemotherapy. If a WOCBP has a urine pregnancy test that cannot be confirmed as negative, a serum (beta-human chorionic gonadotropin \\[â-hCG\\]) pregnancy test will be required.\n11. Participants must have adequate organ function as defined below (Table 1) within 10 days prior to the start of lymphodepleting chemotherapy:\n\n    Table 1. Adequate Organ Function Laboratory Values Systemic Function Test Laboratory Value Hematologic ANC = ≥1500\u002FƒÊL Platelets = ≥100,000\u002FƒÊL Hemoglobin = ≥9.0 g\u002FdLa Renal CrCl by Cockcroft-Gault formula = ≥45 mL\u002Fmin for patients with creatinine \\>1.5 x ULNb Hepatic Total bilirubin = ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \\>1.5 x ULN AST and ALT = ≤2.5 x ULN (≤5 x ULN for patients with history of resected liver metastases) Coagulation PT\u002FINR aPT = ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range\n12. Left ventricular ejection fraction \\>50%. Of note, those patients with risk factors and\u002For with LVEF \\\u003C55% additional testing may need to be performed as per institutional guidelines and\u002For PI guidance.\n13. Adequate respiratory reserve defined as dyspnea Grade 0 or 1 and saturated oxygen \\>92% in room air.\n14. Willing to undergo mandatory blood collections and biopsies as required by the study.\n15. Willing to stay within a 2-hour drive (approximately 100-mile radius) of the study site during the first 4 weeks after the TROP2-NK cell infusion.\n\nExclusion Criteria:\n\n1. Participants with known active disease by RECIST v1.1.\n2. Pregnant, breastfeeding, or expecting to conceive within the projected duration of the study, starting with the screening visit through 6 months post TROP2-CAR-NK cell infusion.\n3. Has received systemic anticancer therapy within 2 weeks or 3 half-lives, whichever is shorter, prior to the start of lymphodepleting chemotherapy. For patients treated with monoclonal antibodies, at least 3 weeks must have elapsed prior to the start of lymphodepleting chemotherapy. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 3 weeks after the last dose of the previous investigational agent.\n4. Participants must have recovered from all AEs due to previous therapies to . Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy, alopecia, or other non-relevant AEs may be deemed eligible at the discretion of the principal investigator (PI). If a participants received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to the start of lymphodepleting chemotherapy.\n5. Has received prior radiotherapy within 2 weeks of the start of lymphodepleting chemotherapy. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis or colitis.\n6. Has received a live vaccine within 6 weeks prior to TROP2-CAR-NK infusion and for at least 24 months post infusion. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette. Guerin, and typhoid vaccine. Seasonal influenza and COVID-19 vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMistR) are live attenuated vaccines and are not allowed.\n7. Prior genetically modified T or NK cell therapy.\n8. Has diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent).\n9. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. The time requirement does not apply to patients who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in situ cancers.\n10. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.\n11. History of interstitial lung disease (ILD) that required steroids or has current pneumonitis\u002FILD.\n12. Active infection requiring systemic therapy.\n13. Known human immunodeficiency virus (HIV) infection.\n14. Known active or chronic hepatitis B or hepatitis C virus infection.\n15. Known history of active tuberculosis (Mycobacterium Tuberculosis).\n16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participants to participate, in the opinion of the treating investigator.\n17. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n18. Has had an allogenic tissue\u002Fsolid organ transplant.\n19. Clinically significant cardiovascular disease within 12 months prior to the start of lymphodepleting chemotherapy, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebrovascular event, or cardiac arrhythmia associated with hemodynamic instability. NOTE: medically controlled arrhythmia would be permitted if meet criteria per Appendix X.\n20. Prolongation of corrected QT interval using Fridericia's formula to \\>480 milliseconds, unless cleared after cardiology evaluation.\n21. Participant with bleeding or thrombotic disorders or at risk for severe hemorrhage. Participants with known deep vein thrombosis\u002Fpulmonary embolism who are on appropriate anti-coagulation treatment are eligible.",{"count":101,"type":21},42,[103],"PHASE1","To find the highest and\u002For recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.",[25,27],"2026-05-18",{"date":108,"type":35},"2026-05-20",{"date":110,"type":35},"2024-12-02",{"date":112,"type":21},"2029-01-18",{"name":92,"class":42},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":76,"phases":124,"briefSummary":125,"conditions":126,"keywords":155,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":43},"100310864","phase-1-ha-1-t-tcr-t-cell-immunotherapy-for-the-treatment-of-patients-with-relapsed-or-refractory-acute-leukemia-after-donor-stem-cell-transplant-100310864","NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant","Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)","Inclusion Criteria:\n\n* Subject age 0-80 years at the time of enrollment.\n* Subject must express HLA-A\\*0201\n* Subject must have the HA-1(H) genotype (RS\\_1801284: A\u002FG, A\u002FA)\n* Subject must have an adult donor for HCT who is adequately HLA matched by institutional standards (includes HLA-matched related or unrelated donors, and HLA-mismatched family donors, including haploidentical donors) and is either:\n\n  * HLA-A\\*0201 positive and HA-1(H) negative (RS\\_1801284: G\u002FG) or\n  * HLA-A\\*0201 negative\n* Subjects who are currently undergoing or who previously underwent allogeneic HCT for\n\n  * Acute myeloid leukemia (AML) of any subtype\n  * Acute lymphoid leukemia (ALL) of any subtype\n  * Mixed phenotype\u002Fundifferentiated\u002Fany other type of acute leukemia, including blastic plasmacytoid dendritic cell neoplasm\n  * Chronic myeloid leukemia with a history of blast crisis and:\n\n    * With relapse or refractory disease (\\>= 5% marrow blasts, or circulating blasts) at any time after HCT\n    * With persistent rising minimal residual disease (defined as detectable disease by morphology, flow cytometry, molecular or cytogenetic testing but \\\u003C 5% marrow blasts by morphology, no circulating blasts on \\>= 2 of two consecutive tests), refractory or ineligible for treatment with tyrosine kinase inhibitors at any time after HCT\n  * Myelodysplastic syndrome (MDS) of any subtype\n  * Chronic myelomonocytic leukemia (CMML)\n  * Juvenile myelomonocytic leukemia (JMML)\n* Subjects must be able to understand and be willing to give informed consent; decision-impaired adults may consent with their legally authorized representative; parent or legal representative will be asked to consent for subjects younger than 18 years old\n* Subjects must agree to participate in long-term follow-up for up to 15 years if they are enrolled in the study and receive T cell infusion\n* Subjects who have relapsed or have MRD after HCT may receive other agents for treatment of disease and remain eligible for the protocol\n* A specific performance status score is not required for enrolling on the protocol; a delay in infusion of the HA-1 TCR T cells may be required for subjects with low performance status\n\nDONOR SELECTION INCLUSION\n\n* Donor age \\>= 18 years\n* Donors must be able to give informed consent\n\nExclusion Criteria:\n\n* Medical or psychological conditions that would make the subject unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)\n* Fertile subjects unwilling to use contraception during and for 12 months after treatment\n* Subjects with a life expectancy of \\\u003C 3 months of enrollment from coexisting disease other than leukemia\n* Subjects who have ongoing grade IV acute GVHD or severe chronic GVHD following most recent transplant. Exception: the principal investigator (PI) may make an exception on a case-by-case basis to include such a subject if there is doubt surrounding the GVHD diagnosis and\u002For sustained significant improvement in GVHD severity\n* The presence of organ toxicities will not necessarily exclude subjects from enrolling on the protocol at the discretion of the PI; however, a delay in the infusion of HA-1 TCR T cells may be required\n\nDONOR SELECTION EXCLUSION\n\n* Donors who are human immunodeficiency virus (HIV)-1, HIV-2, human T-lymphotropic virus (HTLV)-1, HTLV-2 seropositive or with active hepatitis B or hepatitis C virus infection\n* Unrelated donor residing outside of the United States of America (USA) unless the donor screening, testing and leukapheresis occur at an National Marrow Donor Program (NMDP)-affiliated and qualified donor center and are facilitated by the NMDP","80 Years",{"count":123,"type":21},24,[103],"This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T cell receptor is a special protein on T cells that helps them recognize proteins on other cells including leukemia. HA-1 is a protein that is present on the surface of some peoples' blood cells, including leukemia. HA-1 T cell immunotherapy enables genes to be added to the donor cells to make them recognize HA-1 markers on leukemia cells.",[127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,27,151,152,153,154],"Juvenile Myelomonocytic Leukemia","Recurrent Acute Biphenotypic Leukemia","Recurrent Acute Undifferentiated Leukemia","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recurrent Myelodysplastic Syndrome","Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm","Refractory Myelodysplastic Syndrome","Acute Undifferentiated Leukemia","Mixed Phenotype Acute Leukemia","Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive","Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Myelodysplastic Syndrome","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Acute Biphenotypic Leukemia","Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Recurrent Chronic Myelomonocytic Leukemia","Recurrent Mixed Phenotype Acute Leukemia","Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive",[156,157,158,153],"HA-1","TCR","Immunotherapy","2026-05-15",{"date":106,"type":35},{"date":162,"type":35},"2018-02-23",{"date":164,"type":21},"2028-07-16",{"name":166,"class":42},"Fred Hutchinson Cancer Center",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":76,"phases":176,"briefSummary":177,"conditions":178,"keywords":199,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100495785","phase-2-mt2021-08t-cell-receptor-alphabeta-depletion-pbsc-transplantation-for-heme-malignancies-100495785","NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies","Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha\u002FBeta Depletion (A\u002FB TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies","Inclusion Criteria:\n\n* Histological confirmation of hematological malignancies\n* Acute leukemias\n* Acute Myeloid Leukemia (AML) and related precursor neoplasms\n* Favorable risk AML is defined as having one of the following:\n* Acute lymphoblastic leukemia (ALL)\u002Flymphoma\n* Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features.\n* Age 60 years of age or younger at the time of consent\n* Karnofsky performance status ≥ 70% or Lansky play score 50% for ≤16 years of age.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Active uncontrolled infection within 1 week of starting preparative therapy\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR.\n* Any prior autologous or allogeneic transplant\n* CML blast crisis\n* Active central nervous system malignancy","60 Years",{"count":20,"type":21},[78],"This is a phase II, open-label, prospective study of T cell receptor alpha\u002Fbeta depletion (TCR α\u002Fβ TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies. This is a safety\u002Ffeasibility study of the investigational procedure\u002Fproduct.",[179,180,181,146,147,182,183,184,185,186,27,187,127,188,189,190,191,192,193,194,195,196,197,198],"Hematologic Malignancy","Acute Leukemia","Remission","AML","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Myelodysplasia","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin","Lymphoblastic Lymphoma","High Grade Non-Hodgkin's Lymphoma, Adult",[200,201,202,203,204,205,206,207,208,209,210,157],"Bu","Flu","G-CSF","GFSR","aGVHD","HCT","MAC","Mel","PBSCT","PTLD","RECIST","2026-03-31",{"date":213,"type":35},"2026-04-06",{"date":215,"type":35},"2023-05-11",{"date":217,"type":21},"2030-11-30",{"name":219,"class":42},"Masonic Cancer Center, University of Minnesota",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":17,"minAge":228,"maxAge":121,"enrollmentInfo":229,"targetDuration":4,"studyType":76,"phases":231,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":43},"100611947","phase-1-integrating-allogeneic-nk-cells-in-high-risk-advanced-stage-iii-iv-nasopharyngeal-cancer-patients-100611947","NCT07247201","Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","Phase 1\u002F2 Trial Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients","AlloNK1","Inclusion Criteria:\n\n* Diagnosed with NPC Stage III-IVA\u002FB (T1-4, N1-3, M0)\n* Able to tolerate convectional CRT\n* Detectable EBV level at diagnosis\n* Adequate organ function ANC ≥ 1500\u002FµL Platelet count ≥ 100,000\u002FµL Creatinine clearance ≥60ml\u002Fminute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 2 x upper limit normal ALT ≤ 2 x upper limit normal\n* ECOG performance status of 0-1\n\nExclusion Criteria:\n\n* History of Autoimmune Disease or any condition resulting in immunocompromised state (e.g., Drug induced)\n* ECOG performance status above or equal to 2\n* Poor Organ Function\n* Lactating or pregnant\n* Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study.","21 Years",{"count":230,"type":21},31,[103,78],"This clinical trial aims to determine whether Natural Killer (NK) cell therapy administered in combination with concurrent chemoradiotherapy (CRT) can reduce recurrence in patients with advanced nasopharyngeal cancer (NPC), and to identify the highest safe and tolerable dose of allogeneic NK cells. Allogeneic NK cells, derived from healthy donors, have demonstrated good tolerability in cancer patients.\n\nThe primary research questions are:\n\n1. What is the maximum tolerated dose (MTD) of allogeneic NK cells when administered with CRT in NPC patients?\n2. Can the addition of allogeneic NK cells to standard CRT reduce the proportion of NPC patients with detectable plasma EBV-DNA from 30% to 10%?\n\nPhase 1: Participants will receive one of five escalating doses of allogeneic NK cells with CRT to determine the MTD.\n\nPhase 2: Participants will receive the established MTD NK dose together with CRT.\n\nParticipants will undergo regular safety monitoring, side-effect assessment, measurement of plasma EBV-DNA levels, and surveillance for disease recurrence.",[234,27,235,236],"Nasopharyngeal Carcinoma (NPC)","Recurrent Nasopharyngeal Carcinoma","Maximum Tolerated Dose",[238,239,240,236],"Advanced Nasopharyngeal Cancer","Epstein-Barr Virus DNA","Allogeneic NK Cells","NOT_YET_RECRUITING","2026-03-24",{"date":244,"type":35},"2026-03-30",{"date":246,"type":21},"2026-04",{"date":248,"type":21},"2026-09",{"name":250,"class":42},"Singapore General Hospital",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":260,"conditions":261,"keywords":264,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":43},"100615385","to-conduct-multi-omics-integrated-studies-in-peripheral-blood-such-as-fragment-omics-metabolomics-and-epigenetics-and-establish-non-invasive-dynamic-follow-up-monitoring-programs-during-perioperative-and-postoperative-periods-observational-study-100615385","NCT07291921","To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)","Inclusion Criteria:\n\n1. Signed written informed consent.\n2. Male or female, aged ≥ 18 and \\\u003C 85 years.\n3. Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer.\n4. Tumor tissue and blood samples obtainable at all protocol-specified time-points.\n5. No pure ground-glass nodule on imaging.\n6. Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.\n\nExclusion Criteria:\n\n1. Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate\u002Finadequate histology.\n2. Insufficient or poor-quality blood or tissue samples.\n3. Pure ground-glass nodule on imaging.\n4. History of any malignancy within the past 5 years.\n5. Contraindication to surgery preventing radical resection.\n6. Non-radical (R2) resection.\n7. Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections.\n8. Refusal or withdrawal of informed consent.\n9. Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up).","85 Years",{"count":259,"type":21},100,"This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.",[262,263,158,27],"Lung Neoplasms","Neoadjuvant Therapy",[265,266,267,60,268,269,270],"NSCLC","Neoadjuvant immunotherapy","Perioperative monitoring","MRD","Minimal residual disease","Multiple omics","2026-02-27",{"date":273,"type":35},"2026-03-03",{"date":275,"type":35},"2025-05-08",{"date":277,"type":21},"2027-10-31",{"name":279,"class":42},"Peking University People's Hospital",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":76,"phases":288,"briefSummary":290,"conditions":291,"keywords":295,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":4},"100624708","neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial-100624708","NCT07413146","Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\nAge 18 to 70 years (inclusive) at the time of written informed consent. ECOG performance status 0-1, without deterioration within 2 weeks prior to enrollment; anticipated life expectancy ≥12 weeks.\n\nHistologically or cytologically confirmed colon adenocarcinoma, non-MSI-H\u002FdMMR, with pathologic stage (AJCC\u002FUICC TNM 8th edition) of:\n\nHigh-risk stage II, or Stage III. High-risk stage II features include: T4, poor\u002Fundifferentiated histology (high grade; excluding MSI-H), lymphovascular invasion, perineural invasion, preoperative bowel obstruction or tumor perforation, positive\u002Funknown margin status, insufficient margin clearance, \\\u003C12 lymph nodes examined, or high-grade tumor budding.\n\nTumor location consistent with colon cancer: distal tumor margin ≥12 cm from the anal verge on preoperative endoscopy.\n\nBaseline serum CEA \\>5 ng\u002FmL prior to treatment. No evidence of distant metastasis (distant organ and\u002For distant lymph node metastasis) based on comprehensive clinical evaluation.\n\nAbility to provide required clinical data for study collection. Ability to provide adequate fresh tumor tissue from endoscopy and\u002For surgery for WES\u002FNGS to develop an individualized ctDNA MRD panel, and ability to provide required blood samples for ctDNA testing (baseline, postoperative \\~day 7, postoperative \\~day 30).\n\nCandidate for curative-intent R0 resection. Willing and able to comply with the protocol schedule, including regular follow-up visits and necessary treatments, and provides written informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if any of the following apply:\n\nPrior or concurrent other malignant tumor. Any severe comorbidity that, in the investigator's judgment, may significantly affect follow-up or short-term survival.\n\nAny other medical condition, or social\u002Fpsychological circumstance, that in the investigator's judgment makes the participant unsuitable for the study.\n\nMSI-H\u002FdMMR tumor. Evidence of metastatic disease by pathology, clinical assessment, or imaging, including isolated distant lesions, distant disease, or non-contiguous intraperitoneal metastasis.\n\nMultiple primary colon cancers. Underwent open surgery at a non-colon site within 14 days prior to enrollment. Unable to provide required tumor tissue for WES\u002FNGS or personalized MRD panel development, personalized MRD panel customization failure, or unable to provide required blood samples (baseline, postoperative \\~day 7, postoperative \\~day 30).\n\nHistory of blood transfusion within 2 weeks prior to surgery or intraoperatively.\n\nUnable to undergo contrast-enhanced CT or MRI for routine clinical follow-up. Fever ≥38°C within the past 7 days, or clinically significant active infection (including active tuberculosis), or active fungal\u002Fbacterial\u002Fviral infection requiring systemic therapy.\n\nInadequate bone marrow reserve or organ function meeting any of the following laboratory abnormalities (within 1 week prior to testing without corrective treatment):\n\nANC \\\u003C 1.5 × 10⁹\u002FL Platelets \\\u003C 90 × 10⁹\u002FL Hemoglobin \\\u003C 90 g\u002FL (\\\u003C9 g\u002FdL) ALT \\> 3 × ULN AST \\> 3 × ULN or total bilirubin \\> 1.5 × ULN Creatinine \\> 1.5 × ULN or creatinine clearance \\\u003C 45 mL\u002Fmin (Cockcroft-Gault) Albumin \\\u003C 28 g\u002FL Pregnant or breastfeeding, or planning pregnancy during the study period. Any other condition that, in the investigator's judgment, indicates the participant should not participate.","70 Years",{"count":259,"type":21},[289],"NA","The goal of this interventional clinical trial is to compare the efficacy of neoadjuvant chemotherapy versus upfront surgery in adults aged 18-70 years with stage II (high-risk)-III, non-MSI-H colon adenocarcinoma and elevated baseline CEA (\\>5 ng\u002FmL) undergoing curative-intent treatment. This single-center, open-label, randomized controlled study will evaluate 2-year disease-free survival (2y-DFS) as the primary endpoint, with all study-related procedures-including longitudinal ctDNA-based molecular residual disease (MRD) monitoring, Immunoscore assessment, tumor tissue sequencing, and surveillance imaging-provided at no cost to participants. The main questions it aims to answer are:\n\n* Does a treatment strategy involving neoadjuvant CAPOX followed by surgery improve 2y-DFS compared with upfront surgery followed by standard adjuvant chemotherapy?\n* Do postoperative ctDNA-MRD status and its longitudinal dynamics predict 2y-DFS?\n* Does combining ctDNA-MRD with Immunoscore enhance prognostic risk stratification for recurrence beyond either biomarker alone?\n\nParticipants will:\n\n* Be randomized 1:1 (N=100) to one of two treatment pathways:\n\n  * Arm A: Neoadjuvant CAPOX × 4 cycles → curative surgery (R0 planned) → postoperative management per standard practice\n  * Arm B: Upfront curative surgery → postoperative standard adjuvant chemotherapy per guideline → routine surveillance\n* Undergo baseline assessments prior to treatment initiation, including blood draw, colonoscopy, primary tumor next-generation sequencing (for personalized ctDNA-MRD assay development), and Immunoscore testing-all provided free of charge as part of the study.\n* Provide postoperative blood samples for ctDNA-MRD testing at approximately postoperative day \\~7 and day \\~30 (before adjuvant therapy start, if applicable).\n* During follow-up, provide serial blood samples every 3 months, aligned with routine surveillance visits, for repeat ctDNA-MRD analysis.\n* Receive standard-of-care postoperative surveillance (including imaging and clinical evaluations) through 2 years, with all study-mandated assessments covered by the trial.\n\nThis trial integrates clinical intervention with comprehensive biomarker profiling to determine whether early systemic therapy alters MRD dynamics and improves outcomes in high-risk, CEA-elevated colon cancer.",[27,292,293,294],"Immunoscore","Neoadjuvant Chemotherapy","Colon Cancer (Stage II &Amp; III)",[296,27,292,297,298],"advanced stage colon cancer","neoadjuvant chemotherapy","upfront surgery","2026-02-09",{"date":301,"type":35},"2026-02-17",{"date":303,"type":21},"2026-02-24",{"date":305,"type":21},"2027-07-31",{"name":307,"class":42},"Sun Yat-sen University",{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":315,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":337},"100170984","caris-biorepository-research-protocol-100170984","NCT01499394","Caris Biorepository Research Protocol","The Caris Biorepository Research Protocol","Inclusion Criteria:\n\n* 18 years of age or older\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository.\n* Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults.\n* Individuals who lack the capacity to give informed consent",true,{"count":317,"type":21},100000,"The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.\n\nThe Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.",[320,321,27],"Cancer","Early Detection of Cancer",[323,324,325,268,326],"Caris Biorepository","MCED","Early Detection","Pan-Cancer","2026-01-19",{"date":329,"type":35},"2026-01-21",{"date":331,"type":4},"2010-11",{"date":333,"type":21},"2035-11",{"name":335,"class":336},"Caris Science, Inc.","INDUSTRY",38,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":76,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":43},"100619915","predictive-value-of-minimal-residual-disease-for-postoperative-recurrence-and-adjuvant-pd-1-inhibitor-in-hcc-100619915","NCT07350824","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in Hepatocellular Carcinoma: A Prospective, Multicenter Study","Inclusion Criteria:\n\n* Age between 18 and 75 years, inclusive, regardless of gender.\n* Newly diagnosed, treatment-naïve patients with HCC.\n* Received radical treatments, such as liver resection or microwave ablation.\n* Combine at least one of the risk factors for tumor recurrence, such as microvascular\u002Fmacrovascular invasion, poor differentiation, satellite nodules, multiple tumors, and tumor diameter greater than 5 cm.\n* Child-Pugh liver function score ≤ 7.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Absence of severe organic diseases affecting the heart, lungs, brain, or other major organs.\n\nExclusion Criteria:\n\n* History of other malignancies.\n* Recurrent HCC.\n* Prior systemic therapy for HCC.\n* Unable to complete the follow-up and dynamic MRD monitoring.\n* Having an immune deficiency disorder.\n* Allergic to PD-1 inhibitors or unable to tolerate related treatments.","75 Years",{"count":347,"type":21},276,[289],"Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge. Adjuvant immune checkpoint inhibitors (ICIs) show promise in improving outcomes, but biomarkers to identify patients who will benefit are lacking. Current clinicopathological risk factors for minimal residual disease (MRD) are suboptimal in sensitivity and specificity.\n\nCirculating tumor DNA (ctDNA) analysis, reflecting real-time tumor dynamics, offers a promising approach for MRD detection. This study focuses on the methylation status of GNB4 and Riplet-genes located within HCC-associated CpG islands-using a bespoke bisulfite-conversion and qPCR assay to sensitively detect methylated alleles, thereby enabling MRD monitoring.\n\nTo clinically validate this approach, we will conduct a prospective, multicenter cohort study assessing the predictive value of serial \\*GNB4\u002FRiplet\\* methylation testing for recurrence and adjuvant therapy benefit.",[351,27,352],"HCC","Recurrence","2026-01-09",{"date":355,"type":35},"2026-01-20",{"date":357,"type":21},"2025-12-31",{"date":359,"type":21},"2028-12-31",{"name":361,"class":42},"Tongji Hospital",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":43},"100538201","french-assessment-of-mrd-by-liquid-biopsies-in-pdac-patients-frenchmrdpdac-100538201","NCT06287749","French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients","Inclusion Criteria:\n\n* Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.\n* Age 18 years or older.\n* Scheduled for curative intent surgical resection.\n\nExclusion Criteria:\n\n* Hereditary pancreatic cancer.\n* Verified distant metastases.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Adult subject to a legal protection\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":370,"type":21},37,"The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice.\n\nPrimary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence.\n\nSpecifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after\n\n1. curative-intended surgery and\n2. adjuvant chemotherapy.\n\nFRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project",[373,374,27,28,57],"Pancreatic Cancer Resectable","Pancreatic Ductal Adenocarcinoma",[374,373,27,28,57],"2025-07-07",{"date":378,"type":35},"2025-07-10",{"date":380,"type":35},"2024-03-01",{"date":382,"type":21},"2028-10-31",{"name":41,"class":42},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":392,"maxAge":393,"enrollmentInfo":394,"targetDuration":396,"studyType":22,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":43},"100512997","adult-acute-lymphoblastic-leukemia-treated-with-pediatric-regimen-in-brazil-100512997","NCT05959720","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil","Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study","BRALLA","Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20% or more lymphoblasts in bone marrow or peripheral blood.\n\nExclusion Criteria:\n\n* Burkitt leukemia\n* Prior myeloproliferative disease\n* Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype)\n* ECOG\\>2 (appendix 3)\n* Total bilirubin\\>2x upper limit of normal (ULN)\n* Transaminases\\>5x ULN\n* Creatinine\\>2,5 mg\u002Fdl\n* Positive serology for HIV or HTLV\n* Heart failure NYHA Class III or IV (appendix 4)\n* Severe psychiatric disorder which prevents adequate compliance\n* Prior treatment with intravenous chemotherapy\n* Refusal to participate in the study\n* Down syndrome","16 Years","50 Years",{"count":395,"type":21},180,"2 Years","In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic\u002Ffollow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.",[399,27,400,401],"Acute Lymphoid Leukemia","Gene Abnormality","Chemotherapeutic Toxicity","2025-05-03",{"date":404,"type":35},"2025-05-07",{"date":406,"type":35},"2023-09-05",{"date":408,"type":21},"2030-06",{"name":410,"class":42},"Instituto do Cancer do Estado de São Paulo",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":43},"100588483","evaluate-the-clinical-feasibility-of-a-novel-neoantigen-reactive-cd8-t-cell-nart-detection-technology-for-postoperative-mrd-surveillance-of-pancreatic-cancer-100588483","NCT06941987","Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer","Inclusion Criteria:\n\n* age \\>18\n* Assessd as resectable PDAC before surgical procedure\n* Voluntary to donate tumor samples resected in curative surgery for PDAC\n* Voluntary to participate in the radiological evaluation, tests of serum tumor markers, and the collection of MRD samples according to the study protocol\n* ECOG state (PS) grades ≤ 2\n* Voluntary to sign informed consent and adhering to the requirements and limitations outlined by lCD and this protocol\n* Confimed as pancreatic ductal adenocarcinoma by pathology\n* RO or R1 resection\n* Clinically evalutated eligible for adjuvant therapy\n* Tumor tissue samples meet the requirements of whole exome sequencing (WES)\n\nExclusion Criteria:\n\n* Preoperative imaging examinations show distant metastasis\n* Have received neoadjuvant therapy\n* Have any other active malignancy within 5 years before enrollment, or have any other indolent cancers that did not interfere with the primary cancer assessment in the study without prior approval from the research committee\n* With other physical or mental conditions that may increase the risk of study participation or (in the investigator's judgment) may make the subject ineligible for study participation, including recent (within the past year) or active suicidal ideation\u002Fbehavior or laboratory abnormalities\n* Have participated in other interventional or observational clinical studies",{"count":418,"type":21},66,"The goal of this observational study is to learn about the diagnostic performance of a novel Neoantigen-Reactive CD8+ T cell (NART) technology detecting minimal residual disease (MRD) in postoperative surveillance of pancreatic cancer. The main question it aims to answer is: Is NART a sensitive and accurate detection for MRD? Participants are required to undergo periodic blood sampling and imaging examinations as the protocol specifies.",[27,373],"2025-04-19",{"date":423,"type":35},"2025-04-24",{"date":425,"type":21},"2025-04-20",{"date":427,"type":21},"2027-10-20",{"name":429,"class":42},"Shanghai Zhongshan Hospital",{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":76,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":43},"100587624","liquid-biopsy-based-novel-modality-for-postoperative-management-of-lung-cancer-100587624","NCT06930807","Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer","Development and Validation of Non-Invasive Monitoring Techniques for Postoperative Recurrence and Novel Adjuvant Therapeutic Strategies in Lung Cancer","Inclusion Criteria:\n\n* Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy\n* Solid nodules \\>1 cm or ground-glass nodules \\>1.5 cm on imaging\n* No history of malignancies other than non-small cell lung cancer in the past 5 years\n* Specimens are well preserved and imaging documents are accessible.\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Non-small cell lung cancer with pathologic stage IIIB-IV (8th edition TNM classification)\n* Pathology results confirmed not to be non-small cell lung cancer\n* History of malignancies other than non-small cell lung cancer in the past 5 years",{"count":438,"type":21},1000,[289],"The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are:\n\n* How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurrence in lung cancer?\n* Is adaptive treatment guided by ctDNA-MRD for lung cancer patients superior to traditional clinical management and effectively improves survival?\n* Do heterogeneous patient populations (grouped by stages, histopathological subtypes, driver mutations, and treatment histories) show differences in effects under ctDNA-MRD guided postoperative management strategies?",[442,27,443],"Non-small Cell Lung Cancer","Adaptive Treatment","2025-04-08",{"date":446,"type":35},"2025-04-16",{"date":448,"type":35},"2025-03-25",{"date":450,"type":21},"2028-07-31",{"name":279,"class":42},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":76,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":43},"100584141","infusion-of-alloreactive-nk-cells-for-mrd-positive-aml-patients-100584141","NCT06885476","Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients","Infusion of Alloreactive nk Cells for Acute Myeloid Leukemia Patients, Eligible for Allogeneic Stem Cell Transplantiation, With Persistent Minimal Residual Disease After Conventional Chemotherapy","Inclusion Criteria:\n\n* Diagnosis of de novo or secondary AML\n* Age ≥ 18 years\n* Morphologic CR\n* Eligibility for ASCT\n* MRD-positivity after induction chemotherapy\n* Availability of a KIR-L incompatible haploidentical donor\n* Performance Status ≥ 70% (Karnofsky score) or ≤ 2 (WHO).\n* Adequate renal (serum creatinine \\\u003C 2 mg\u002Fdl), pulmonary (Sat O2 ≥ 96%) and hepatic (ALT\u002FAST \\\u003C 2.5 x N) function.\n* Left Ventricular Ejection Fraction (LVEF) of \\>50% as determined by Echocardiogram (ECHO).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of AML FAB M3\n* HIV positivity.\n* HCV positivity with high viral load.\n* Pregnant or nursing females.\n* Current uncontrolled infection.\n* Signs or symptoms of fluid retention (e.g. pleural effusion).",{"count":460,"type":21},22,[289],"This is a interventional, transplantation study. The procedure under study is the infusion of alloreactive NK cells in adult AML patients, eligible for ASCT, who achieved CR after conventional chemotherapy, but harbor MRD-positivity.\n\nHaploidentical KIR-L mismatched donors will be included if present at least one allele mismatch at a class I locus among the following ones: HLA-C alleles with Asn77-Lys80, HLA-C alleles with Ser77-Asn80, HLA-Bw4 alleles. KIR-L mismatched donor alloreactive NK cell repertoire will be evaluated in order to determine the functional cell dose to be used for NK cell collection. Phenotypical analysis of KIRs will be correlated to functional tests. NK cells will be selected from a steady-state large volume leukapheresis product from a suitable haploidentical KIR-ligand incompatible donor. NK cell purification will be performed if the donor leukapheresis product contains at least 10x106 NK cells\u002FKg.\n\nImmunomagnetic enrichment of NK cells will follow two subsequent steps: 1) depletion of CD3+ T cells followed by 2) positive selection of CD56+ NK cells.\n\nPatients will receive immunosuppressive chemotherapy, fludarabine (Flu) 25 mg\u002Fmq\u002F from day -5 to -3 and cyclophosphamide (Cy) 2 g\u002Fmq on day -2 (Flu\u002FCy). Two days after Cy administration, patients will be infused intravenously with a single dose of cryopreserved NK cells (day 0), which will be followed by subcutaneous administration of IL-2 (10 x 106 IU\u002Fday, 3 times weekly) for 2 weeks (6 doses total). PB samples will also be collected for biological studies. In particular, PB samples will be collected for molecular assessment of microchimerism and tracking of haploidentical NK cells for 30 days, immunophenotype studies, alloreactive NK cells cloning and functional assays (cytotoxicity). Enrolled patients will be followed up for at least 12 months after NK cell infusion.",[146,27,464],"Natural Killer Cell","2025-03-18",{"date":467,"type":35},"2025-03-20",{"date":469,"type":35},"2021-01-22",{"date":471,"type":21},"2026-12",{"name":473,"class":42},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":482,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":501},"100533774","ctdna-based-mrd-testing-for-nac-monitoring-in-tnbc-100533774","NCT06230185","CtDNA Based MRD Testing for NAC Monitoring in TNBC","Breast Cancer-Minimal\u002FMolecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)","B-STRONGER-I","Inclusion Criteria:\n\n1. Have histologically documented TNBC (defined as ER expression ≤10% by IHC, PR expression≤10% by IHC and HER2 0 or 1+ by IHC or FISH ratio \\\u003C2 or HER2 gene copy number of \\\u003C6).\n2. Early-stage breast cancer (stage I-III) and scheduled to undergo NAC treatment with curative intent.\n3. Be informed of the investigational nature of the study and all pertinent aspects of the trial.\n4. Have the ability to understand and the willingness to sign a written informed consent document in accordance with institutional and federal guidelines.\n5. Be ≥ 18years of age.\n6. Patient who are scheduled to start NAC.\n7. Be willing to provide blood samples before and during treatment.\n8. Have available biopsy tissue.\n\nExclusion Criteria:\n\n1. Receiving concurrent anti-neoplastic therapy for another malignancy.\n2. Stage IV disease.\n3. Current or history of another primary cancer within 5 years of study entry, with the exception of basal or squamous cell skin cancer, or non-invasive malignancy.\n4. History of allogeneic bone marrow or organ transplant.\n5. Blood transfusion within two weeks before collection of blood for central ctDNA testing.\n6. Started systemic therapy for their breast cancer.\n7. Pregnancy","FEMALE",{"count":484,"type":21},422,"A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.",[487,27],"TNBC - Triple-Negative Breast Cancer",[57,28,489,268,490,491,492],"Breast Cancer","NAC","TNBC","NeXT Personal®","2025-01-03",{"date":495,"type":35},"2025-01-07",{"date":497,"type":35},"2023-11-09",{"date":357,"type":21},{"name":500,"class":336},"Personalis Inc.",14,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":508,"maxAge":18,"enrollmentInfo":509,"targetDuration":4,"studyType":76,"phases":511,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":4},"100574747","ngs-mrd-guided-blinatumomab-treatment-for-pediatric-b-all-100574747","NCT06763302","NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","Inclusion Criteria:\n\n* Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).\n* Age ≥1 year and \\\u003C18 years.\n* Informed consent signed, with the parents or guardians agreeing to a unified treatment protocol.\n\nExclusion Criteria:\n\n* Age \\\u003C1 year or ≥18 years.\n* Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.\n* Secondary leukemia or second tumor, CML blast phase ALL.\n* Other tumors or immunodeficiency diseases present.","1 Year",{"count":510,"type":21},1220,[289],"The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.\n\nThe main questions it aims to answer are:\n\n1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy?\n2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?",[514,515,27,516],"B Cell Precursor Acute Lymphoblastic Leukemia","Pediatric","Next Generation Sequencing (NGS)","2025-01-02",{"date":519,"type":35},"2025-01-08",{"date":521,"type":21},"2025-01-01",{"date":523,"type":21},"2030-12-31",{"name":525,"class":42},"The Children's Hospital of Zhejiang University School of Medicine",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":315,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":43},"100398278","better-leukemia-diagnostics-through-ai-beluga-100398278","NCT04466059","Better Leukemia Diagnostics Through AI (BELUGA)","A Case-Control Study To Determine The Suitability Of Artificial Intelligence For Leukemia Diagnostics","BELUGA","Inclusion Criteria:\n\n* Patients having been diagnosed with a suspected hematological disorder\n* The suspected diagnoses constitute a primary diagnosis\n* Only samples of patients min.18 years of age will be used\n* Samples must suffice quality attributes which are denoted in \"Exclusion Criteria\"\n\nExclusion Criteria:\n\n* The sample is not fit for state-of-the-art diagnosis or fails initial quality control. For quality insurance, we will exclude samples in heparin- instead of EDTA. Samples with damage due to atmospheric reasons (freeze-thaw damage or elevated temperature) will be excluded.\n* Samples with too scarce material jeopardizing routine gold-standard diagnosis will be excluded.\n* Bone marrow aspirates without sufficient material to assess malignant or healthy hematopoiesis.",{"count":535,"type":21},25000,"To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms. Taking advantage of an unprecedented collection of diagnostic samples consisting of flow cytometry datapoints and digitalized blood-smears, categorization of yet undiagnosed patient samples will prospectively be compared to current state-of-the-art diagnosis at the Munich Leukemia Laboratory (hereafter MLL). In total, a collection of 25,000 digitalized blood smears and 25,000 flow cytometry datapoints will be prospectively used to train an AI-based deep neuronal network for correct categorization. Subsequently, the superiority will be challenged for the primary endpoints: sensitivity and specificity of diagnosis, most probable diagnosis, and time to diagnose. The secondary endpoints will compare the consequences regarding further diagnostic work-up and, thus, clinical decision making between routine diagnosis and AI guided diagnostics. BELUGA will set the stage for the introduction of AI-based hematologic diagnostics in a real-world setting.",[179,153,27,538,539],"Lymphoma","Blood Cancer",[541,542,543,544,545],"hematology","laboratory medicine","AI-based diagnostics","artificial intelligence","deep neuronal networks","2024-12-14",{"date":548,"type":35},"2024-12-17",{"date":550,"type":35},"2020-01-05",{"date":552,"type":21},"2025-07-31",{"name":554,"class":336},"Munich Leukemia Laboratory",{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":562,"targetDuration":4,"studyType":76,"phases":564,"briefSummary":565,"conditions":566,"keywords":570,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":43},"100557349","phase-2-va-combined-with-pd-1-inhibitor-for-the-treatment-of-relapsed-and-refractory-aml-and-high-risk-mds-100557349","NCT06536959","VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS","A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS","Inclusion Criteria:\n\n* Patients diagnosed with relapsed and refractory acute myeloid leukemia (AML) and patients diagnosed with myelodysplastic syndrome (MDS) who require chemotherapy treatment.\n* Patients who did not respond or had disease recurrence after 1 course of induction chemotherapy or had positive immune residues after induction chemotherapy or positive molecular residues (if any) after induction chemotherapy.\n* Voluntarily participate in clinical research and sign an informed consent form and be willing to follow and be able to complete all experimental procedures.\n* The toxic and side effects caused by the last treatment should be recovered.\n* Eastern Cooperative Oncology Group score of 0 to 3 points.\n* The organ function is intact.\n\n  * Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2×ULN (Upper Limit of Normal).\n  * Creatinine≤2×ULN.\n  * Bilirubin≤2×ULN.\n* Karnofsky≥70.\n* The expected survival period is at least 12 weeks.\n* Non-pregnant, non-breastfeeding women.\n\nExclusion Criteria:\n\n* Suffering from other untreated or unrelieved malignant tumors within 2 years.\n* Major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, and experimental therapy were performed within 2 weeks of the first medication.\n* Suffering from any other known serious and\u002For uncontrolled disease (eg, uncontrolled diabetes; cardiovascular disease, including congestive heart failure New York Heart Association \\[NYHA\\] Class III or IV, 6 months patients with myocardial infarction and poorly controlled blood pressure); chronic renal failure; or active uncontrolled infection); the investigators considered unsuitable for this clinical trial.\n* Patients who are unwilling or unable to comply with the protocol.\n* Currently being treated with other systemic anti-tumor or anti-tumor research drugs.\n* Women who are pregnant or breastfeeding.",{"count":563,"type":21},67,[78],"The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed\u002Frefractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain. In this study, the investigators aimed to assess safety and response to a new PD-1 inhibitor-based triple-drug combination regimen (venetoclax + hypomethylation agent + PD-1 inhibitor) in relapsed\u002Frefractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients, or who had positive minimal residual disease.",[567,568,569,27],"Relapsed Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","Myelodysplastic Syndromes",[571,572,573],"Venetoclax","Hypomethylation agen","PD-1 inhibitor","2024-07-31",{"date":576,"type":35},"2024-08-05",{"date":578,"type":35},"2024-07-18",{"date":305,"type":21},{"name":581,"class":42},"Beijing 302 Hospital",{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":268,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":43},"100524477","a-perspective-study-of-the-mrd-tailored-therapy-in-patients-with-newly-diagnosed-multiple-myeloma-with-persistent-minimal-residual-disease-after-initial-treatment-100524477","NCT06109233","A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment","Inclusion Criteria:\n\n1. Subject must be at least 18 years of age.\n2. Subject must have documented newly diagnosed symptomatic multiple myeloma as defined by 2014 International Myeloma Working Group criteria.\n3. Subject must have achieved a response (partial response \\[PR\\] or better based on investigator's determination of response by the IMWG criteria) to at one prior regimen.\n4. Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. Contraception must begin 4 weeks prior to dosing and continue until at least 3 months after receiving the last dose of the study drug. A woman of childbearing potential must have a negative serum or urine pregnancy tests at screening within 14 days prior to randomization.\n5. Each subject (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study.\n\nExclusion Criteria:\n\n1. Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma. Monoclonal gammopathy of undetermined significance is defined by presence of serum M-protein \\\u003C3 g\u002FdL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein; and (if determined) proportion of plasma cells in the bone marrow of 10% or less. Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with absence of related organ or tissue impairment or end-organ damage.\n2. Relapsed and refractory myeloma：Relapsed and refractory myeloma is defined as disease that is nonresponsive while on salvage therapy, or progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better at some point previously before then progressing in their disease course.\n3. Primary refractory myeloma：Primary refractory myeloma is defined as disease that is nonresponsive in patients who have never achieved a minimal response or better with any therapy.\n4. Subject is known or suspected of not being able to comply with the study protocol。 Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject or that could prevent, limit, or confound the protocol-specified assessments.",{"count":589,"type":21},80,"The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous hematopoietic stem cell transplantation or consolidation of the original regimen) who were switched to high-intensity therapy, and to compare the rate of persistent MRD-negativity, progression-free survival (PFS), and overall survival (OS) between the two groups in comparison with NDMM patients who achieved MRD-negativity after the same induction and consolidation therapy.",[592,27],"Multiple Myeloma",[592,594,595,596,597],"MRD-tailored therapy","MRD status","MRD-negative rates","Survival","2024-07-03",{"date":600,"type":35},"2024-07-05",{"date":602,"type":35},"2022-01-10",{"date":604,"type":21},"2026-01-10",{"name":606,"class":42},"FengYan Jin",{"id":608,"slug":609,"hasResults":12,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":286,"enrollmentInfo":614,"targetDuration":396,"studyType":22,"phases":4,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":43},"100551717","primary-multiple-myeloma-who-achieved-mrd-negativity-after-induction-therapy-asct-or-not-100551717","NCT06463717","Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not","Comparing the Efficacy and Safety of Autologous Hematopoietic Stem-cell Transplantation Versus Non Transplantation Regimen in Primary Multiple Myeloma Achieved MRD Negativity After Induction: A Multiple Center, Prospective Cohort Study","Inclusion Criteria:\n\n1. Newly diagnosed multiple myeloma according to the criteria of International Working Group of Myeloma\n2. Age ranges from 18-70 years old\n3. Achieved MRD negativity and at least very good partial response in clinical response after 4-6 courses of induction therapy. MRD is measured by MRD by multicolor flow with a sensitivity of 10-5.\n4. At enrollment, score of Eastern Cooperative Oncology Group (ECOG) should be 0-2.\n5. Organ function requirement: Blood bilirubin ≤ 2mg\u002FdL (35 μ mol\u002FL), Alanine aminotransferase\u002FAspartate aminotransferase below 2 times the upper limit of normal value, Creatinine clearance rate (Ccr) ≥ 30ml\u002Fmin and Cardiac ejection fraction ≥50%.\n6. Expected survival more than 3 months.\n\nExclusion Criteria:\n\n1. Two or more high-risk cytogenetic abnormalities, including del (17p), t (4; 14), t (14; 16), del (1p), amp (1q). Fluorescence in situ hybridization was used to analyze CD138 positive sorted cells, with cut off value of 15% for translocation, 10% for deletion, and amp (1q) of 20%.\n2. Extracellular plasma cell disease, central invasion of myeloma, plasma cell leukemia\n3. History of other malignant tumors within the past 5 years\n4. Patients with HIV, active tuberculosis, clinically active hepatitis A, B, or C\n5. Other serious condition that may restrict patients from continuing treatment (such as advanced infection, uncontrolled diabetes, severe cardiac insufficiency, or angina pectoris)\n6. General condition not suitable for chemotherapy\n7. Pregnant or lactating women\n8. Suffering from other serious organic diseases and mental disorders.",{"count":615,"type":21},210,"The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after induction.\n\nThe main question it aims to answer is:\n\nIn primary multiple myeloma patients who achieved MRD negativity after induction, non ASCT regimens are not inferior to ASCT or not? Participants will receive ASCT or non ASCT regimen according to their own choice.\n\nResearchers will compare ASCT and non ASCT group see if any significant difference in efficacy and safety.",[592,27],[619,620],"Minimal Residual Disease Negativity","Autologous Stem Cell Transplantation","2024-06-21",{"date":623,"type":35},"2024-06-24",{"date":625,"type":35},"2023-12-01",{"date":627,"type":21},"2028-12",{"name":629,"class":42},"First Affiliated Hospital of Zhejiang University",{"id":631,"slug":632,"hasResults":12,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":76,"phases":639,"briefSummary":640,"conditions":641,"keywords":643,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":4},"100523066","kinetics-and-impact-on-survival-of-mrd-in-aml-patients-receiving-azacitidine-and-venetoclax-100523066","NCT06090786","Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax","A Multicentric, Prospective Study Addressing the Kinetics and Impact on Survival of Measurable Residual Disease in Acute Myeloid Leukemia Patients Receiving Azacitidine and Venetoclax","Inclusion Criteria:\n\n* Subject must be ≥ 18 years of age\n* Subject has diagnosis of AML according to WHO 2016\n* Subject has newly diagnosed, previously untreated, AML, including de novo, secondary and therapy-related (cytoreduction with hydroxyurea is admitted prior treatment start)\n* Subject is planned to receive front-line therapy with Azacitidine and Venetoclax\n* Subject is ineligible for intensive induction chemotherapy according to investigator assessment according to clinical practice\n* Subject must have assessable MRD by flow cytometry at screening BM evaluation\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national local laws\n\nExclusion Criteria:\n\n* Diagnosis of BCR::ABL1-positive AML\n* Diagnosis of APL\n* AML with CNS involvement.\n* AML with extra-medullary localizations\n* Patients' unwillingness or inability to comply with the protocol requirements.",{"count":638,"type":21},225,[289],"The goal of this no-profit, multicenter, biological, non-pharmacologic study is to evaluate minimal residual disease (MRD) in patients treated with Azacitidine and Venetoclax according to clinical practice.\n\nThe main questions it aims to answer are:\n\n1. kinetics of disease response on treatment with Azacitidine and Venetoclax through the evaluation of MRD with both cytofluorimetric and molecular techniques\n2. impact of MRD on survival outcomes. To this end, bone marrow samples will be collected at pre-defined time-points during treatment and MRD will be assessed.",[642,27],"AML, Adult",[571,644,182,645],"Azacitidine","Minimal rsidual disease","2024-04-09",{"date":648,"type":35},"2024-04-10",{"date":650,"type":21},"2024-07",{"date":652,"type":21},"2027-07",{"name":654,"class":42},"Gruppo Italiano Malattie EMatologiche dell'Adulto",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":662,"targetDuration":4,"studyType":76,"phases":664,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":241,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100540922","phase-3-adjuvant-target-therapy-guided-by-ctdna-mrd-in-patients-with-egfr-mutant-ii-iiia-non-small-cell-lung-cancer-ectop-1022-100540922","NCT06323148","Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA","Inclusion Criteria:\n\n1. Age greater than 18 years old, both males and females are eligible.\n2. Histologically confirmed diagnosis of non-small cell lung cancer.\n3. Diagnosis of stage II-IIIA (N1-N2) non-small cell lung cancer based on the 8th edition TNM staging guidelines combined with radiological evaluation.\n4. EGFR mutation-positive status confirmed through molecular testing (such as ARMS-PCR or high-throughput sequencing), specifically with mutations 19del or 21L858R.\n5. Able to undergo R0 surgical resection.\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1. Expected survival of more than 12 months.\n7. Baseline blood routine and biochemical indicators meeting the following criteria:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n   * Lymphocyte count ≥ 0.5 × 10\\^9\u002FL;\n   * Platelet count ≥ 100 × 10\\^9\u002FL;\n   * Hemoglobin ≥ 9 g\u002FdL.\n   * Total bilirubin ≤ 1.5 times the upper limit of normal (ULN);\n   * Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 times ULN.\n8. Patients must provide informed consent, either directly or through their legally authorized representatives, after being informed about the study.\n\nExclusion Criteria:\n\n1. Pathological diagnosis of mixed-type lung cancer (including a history of small cell lung cancer or non-adenocarcinoma).\n2. Received anti-tumor therapy before surgery (including radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.).\n3. Rx, R1, R2 surgical resection.\n4. Received blood transfusion during surgery or within 2 weeks before surgery.\n5. Pregnant or lactating female patients.\n6. History of other malignant tumors within the past 5 years, except for cases where other malignant tumors have been cured solely through surgery with a disease-free interval of at least 10 years, curable basal cell carcinoma of the skin, and cervical carcinoma in situ.\n7. Any unstable systemic diseases (including active infections, uncontrolled hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within the past year, severe arrhythmias requiring medication, liver, kidney, or metabolic diseases).\n8. Evidence of any other diseases, neurological or metabolic functional disorders, physical examination findings, or laboratory findings that would place the subject at high risk of treatment-related complications.\n9. Other factors deemed by the investigators to potentially affect the study process.",{"count":663,"type":21},226,[665],"PHASE3","This study plans to conduct ctDNA testing on EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients after radical surgery (R0 resection). Patients with positive ctDNA testing will receive standard treatment according to clinical guidelines, while patients with negative ctDNA testing will be assessed based on comprehensive clinical and pathological characteristics. After receiving or not receiving standard adjuvant chemotherapy, patients will be randomly assigned in a 1:1 ratio to either the observation follow-up group (experimental group) or the osimertinib adjuvant treatment group (control group). The aim is to explore whether observation follow-up for patients with negative ctDNA after surgery has a prognosis non-inferior to osimertinib treatment, and to investigate the disease-free survival rate of EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients with positive ctDNA after surgery receiving osimertinib adjuvant treatment, providing more precise treatment guidance for adjuvant therapy in this specific type of NSCLC patients with EGFR mutation-positive tumors.",[668,669,27],"Lung Cancer","EGFR Gene Mutation","2024-03-14",{"date":672,"type":35},"2024-03-21",{"date":674,"type":21},"2024-04-01",{"date":676,"type":21},"2029-03-31",{"name":678,"class":42},"Fudan University",{"id":680,"slug":681,"hasResults":12,"nctId":682,"briefTitle":683,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":76,"phases":687,"briefSummary":688,"conditions":689,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":694,"leadSponsor":695,"locationsCount":43},"100521231","a-study-of-chidamide-with-aza-in-mrd-positive-aml-after-transplant-100521231","NCT06066905","A Study of Chidamide With AZA in MRD Positive AML After Transplant","Inclusion Criteria:\n\n1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);\n2. ≥18 years old;\n3. ECOG≤3;\n4. lifespan≥3 months;\n5. Take contraceptive measures;\n6. Sign informed consent.\n\nExclusion Criteria:\n\n1. Allergic to the study drug;\n2. A gastrointestinal condition that prevents oral medication;\n3. active infection;\n4. Dysfunction of vital organs;\n5. other malignancies;\n6. HIV infection;\n7. HBV or HCV;\n8. The QT interval is prolonged;\n9. Pregnant or lactating women;\n10. Is participating in other clinical studies;\n11. The researchers did not consider it appropriate to participate in this study.",{"count":686,"type":21},60,[289],"acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.",[642,27],"2023-10-26",{"date":692,"type":35},"2023-10-27",{"date":690,"type":21},{"date":471,"type":21},{"name":696,"class":42},"Guangdong Provincial People's Hospital"]